Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

14

Revenue 2017

Opdivo

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Opdivo was produced by Gilead Sciences.

HTA guidance from NICE, the SMC and the AWMSG

England's cost effectiveness watchdog NICE has recommended BMS' Opdivo  as an adjuvant treatment for skin cancer, reversing its initial decision. ... NICE has said the drugmaker needs to compare Opdivo with. 22 Nov 2018.

EU approval for Opdivo combo in renal cell cancer

EU approval for Opdivo combo in renal cell cancer Median OS in patients treated with Opdivo plus low-dose Yervoy was not yet reached, compared to 25.9 months for patients treated with sunitinib. ... The European approval is important for BMS, as it seeks to maintain Opdivo’s blockbuster growth,

Chinese biotechs aim PD-L1 antibody at hepatitis B

Chinese biotechs aim PD-L1 antibody at hepatitis B Front-runners in the immuno-oncology category such as Bristol-Myers Squibb (BMS) with Opdivo (nivolumab) and Merck &Co/MSD with Keytruda (pembrolizumab) have not started trialling their blockbuster drugs in

Nektar confirms BMS deal for NKTR-214 is on track

Nektar confirms BMS deal for NKTR-214 is on track Nektar disclosed data from the PIVOT trial of NKTR-214 plus BMS’ PD-1 inhibitor Opdivo (nivolumab) at the ASCO meeting last year, although the two companies were forced to defend

BMS and Celgene announce $74bn merger

BMS and Celgene announce $74bn merger BMS and Celgene have each had their travails in recent times: BMS has seen its first-to-market immunotherapy Opdivo overtaken by Merck &Co’s rival Keytruda, while Celgene suffered numerous

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...
Alzheimer’s disease – is Europe prepared if a breakthrough treatment becomes available?
Healthcare leaders in the European Union should begin preparing for a breakthrough now...
The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...

Infographics